OKYO Pharma (OKYO) director buys 22,500 shares in open-market trade

Rhea-AI Filing Summary

OKYO Pharma Ltd reported that director and ten percent owner Gabriele M Cerrone, through Panetta Partners Limited, purchased 22,500 shares of common stock on July 21, 2026 in an open-market transaction at $1.45 per share. After this indirect purchase, the associated entity holds 10,873,916 common shares. This amended filing solely corrects the transaction code and reflects a trade not made under a Rule 10b5-1 plan.

Insider Trade Summary

Net Buyer: 22,500 shares

Net Buy 1 txn

Insider CERRONE GABRIELE M

Role Director, 10% Owner

Bought 22,500 shs ($33K)

Type	Security	Shares	Price	Value
Purchase	COMMON STOCK	22,500	$1.45	$33K

Holdings After Transaction: COMMON STOCK — 10,873,916 shares (Indirect, Via Panetta Partners Limited)

Key Figures

Shares purchased: 22500 shares Purchase price: $1.4500 per share Indirect holdings after trade: 10873916 shares +1 more

4 metrics

Shares purchased 22500 shares Common stock bought on 2026-07-21 in open market

Purchase price $1.4500 per share Price paid for common stock in the reported transaction

Indirect holdings after trade 10873916 shares Common stock held indirectly following the transaction

Net buy shares 22500 shares Net shares bought across all transactions in this filing

Key Terms

open market purchase, ten percent owner, Via Panetta Partners Limited

3 terms

open market purchase financial

"correct the transaction code associated with this open market purchase"

An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.

ten percent owner financial

"reporting person is listed as a director and ten percent owner"

Via Panetta Partners Limited financial

"nature of ownership is reported as Via Panetta Partners Limited"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/07/2026 - 04:16 PM Accepted by SEC EDGAR 08/07/2026 - 04:15 PM Learn about SEC filing dates

FAQ

What insider share purchase did OKYO (OKYO) disclose in this Form 4/A?

OKYO Pharma disclosed that an entity associated with director and ten percent owner Gabriele M Cerrone bought 22,500 common shares on July 21, 2026 in an open-market purchase at $1.45 per share, reported as indirect ownership.

Who executed the OKYO (OKYO) share purchase and in what capacity?

The purchase was reported by Gabriele M Cerrone, a director and ten percent owner of OKYO Pharma. The shares are held indirectly through Panetta Partners Limited, an entity associated with the reporting person.

How many OKYO (OKYO) shares are now held indirectly after this transaction?

Following the reported open-market purchase, the entity associated with the reporting person holds 10,873,916 shares of OKYO Pharma common stock indirectly, as stated as the total shares following the transaction.

Was the reported OKYO (OKYO) insider trade under a Rule 10b5-1 plan?

No. The Rule 10b5-1 checkbox is not marked, and there is no footnote indicating a trading plan. The transaction is therefore reported as a non-Rule 10b5-1 open-market purchase.

Why did OKYO (OKYO) file this Form 4/A amendment?

The amendment was filed solely to correct the transaction code associated with the reported open-market purchase. The company states that no other reported transactions are affected or changed by this Form 4/A.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CERRONE GABRIELE M

(Last) (First) (Middle)

14-15 CONDUIT ST

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/23/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	07/21/2026		P		22,500	A	$1.45	10,873,916	I	Via Panetta Partners Limited

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4/A amends the Form 4 filed on July 23, 2026 solely to correct the transaction code associated with this open market purchase. No other reported transactions are affected by this amendment.

	/s/ Gabriele M. Cerrone	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)